The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years.
Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing, partnerships or global biopharma buy-outs.
To hear more about the findings, please read the latest report by the Deloitte Life Sciences Catalyst team.
https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-scienc…
Source LDPath’s outstanding digital integration with East Kent Hospital NHS Foundation Trust (EKHUFT) pathology department has been selected as the winner of the “Best Hospital Technology Implementation” award in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.
The integration was finalised in June 2022 to digitise the pathology department of the Trust, which has greatly reduced their cancer diagnostic reporting times. The success seen in this collaboration between Source LDPath and EKHUFT has been recognised as a clinical success for improving overall…
o2h group, the creators of innovative SciTech communities, has launched the Cambridge Wide Open Day, offering a unique insight into the city best known as the ‘UK Centre of Science & Technology’. The inaugural event will take place on Wednesday 14 June 2023, welcoming science enthusiasts and local residents alike from across the Cambridge community – giving everyone the opportunity to explore the city’s world-class science and technology facilities all in one day.
After setting up a new Department of Science, Innovation, and Technology in February 2023, the UK government published its ‘…
Howard Group appoints Jon Green as Director – Unity Campus
Experienced life sciences executive and site leader to take on the role
from June this year
Cambridge, 02 May 2023: Leading regional property investor and developer Howard Group is delighted to announce the appointment of Jon Green to the role of Director – Unity Campus.
Jon is an exceptionally experienced site leader with extensive strategic business operations and scientific experience within the commercial life sciences arena. Well-known and respected, particularly within the Cambridge…
April 2023 marks five years since Medicines Discovery Catapult (MDC), an independent, not-for-profit national innovation centre for drug discovery, actively began reshaping drug discovery for patient benefit.
To mark this milestone, MDC has launched an impact showcase site, offering an immersive insight into a selection of MDC's work through the lens of its collaborations and initiatives.
From their base in Cheshire, MDC transforms great UK science into better treatments through partnerships. It has delivered over 230 projects with over 170 partners across the UK - helping UK companies…
In a move that will build on its leading position in the market and bring together experts across the business, Partners& has launched a national science and technology practice.
In line with the UK government’s commitment to focusing on the growth and development of this important part of our economy, Partners& is positioning itself to deliver a unique proposition to this complex, fast moving and innovative sector.
Led by Hanna Beaumont, Client Partner (Science & Tech), the Partners& team has rich experience and specialist insight into the challenges and risks inherent in…
Check out your monthly round up of employee engagement opportunities in this month's People Pathways newsletter!
Arecor Therapeutics plc
(“Arecor” or the “Group”)
US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES
- Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market
- Further strengthens Group’s extensive patent portfolio
Cambridge, UK, 26 April 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11608357)…
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced a collaborative services agreement between Physiomics PLC and ValiRx subsidiary company, Inaphaea BioLabs Ltd.
Based in Oxford, Physiomics is a leading oncology consultancy that uses mathematical models to support the development of cancer treatment regimens and personalised medicine solutions.
The agreement recognises the synergy between Inaphaea’s ambition to create a translational contract research organisation (tCRO™) and Physiomics’ capabilities across advanced statistical…